TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data Private Market Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Acelyrin Stock

Acelyrin Stock

acelyrin.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $558MM

Acelyrin is a biopharma company that invests in, develops and commercializes life-changing innovative therapeutics and transformative medicines. Acelyrin partners with big pharmaceutical companies, early-stage startups, and academia with a blend of scientific, medical, operational, and company-building experience to bring its treatments and therapeutics to the public, and transform patient's lives through healing and wellbeing.

Buy or sell Acelyrin stockLearn more about Acelyrin IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Acelyrin, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Acelyrin’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Acelyrin.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Acelyrin investors also invested in these private companies

Cowen Group
Marshall Wace
Matrix Partners
Decheng Capital
Westlake Village BioPartners
OrbiMed Healthcare Fund Management
Samsara Biocapital
venBio
RTW Investments
Surveyor
Tybourne Capital Management

Team

Management Team

Shao-Lee Lin, MD, PhD
Chief Executive Officer
Robert F. Carey
President
Paul Peloso
Chief Medical Officer
Melanie Gloria
Chief Operating Officer
Gil Labrucherie
Chief Financial Officer
Ron Oyston
Senior Vice President, Human Resources
Marc Kubasak
Vice President, Program Lead & Regulatory Affairs
Brian Wiens
Vice President, Biostatistics and Data Sciences
Terry Bevirt
Vice President, Alliance Management, Clinical & Corporate Quality
Katherine To
Vice President - Clinical Operations
Suzy Buckhalter
Senior Director, Finance & Accounting
Tyler Marciniak
Head of Investor Relations and Communications
Shawn Eisnberg
Vice President, Technical Operations

Board Members

Sean Harper
Kin Insurance
Alan Colowick
Sofinnova Investments
Beth Seidenberg
Westlake Village BioPartners
Dan Becker
Access Biotechnology
Richard Gaster
venBio Partners

Frequently Asked Questions About Acelyrin’s Stock

plusminus
Can you buy Acelyrin stock?
Acelyrin is not publicly traded on NYSE or NASDAQ in the U.S. To buy Acelyrin stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Acelyrin stock?
Yes, you can sell stock of a private company like Acelyrin. Forge can help you sell your Acelyrin stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Acelyrin’s stock price?
Acelyrin is a privately held company and therefore does not have a public stock price. However, you may access Acelyrin’s private market stock price with Forge Data.
plusminus
What is Acelyrin’s stock ticker symbol?
Acelyrin does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Acelyrin in the BioTech & Pharma sector

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$3.67B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

Atomwise

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$405.17MM

Mammoth Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.08B

Biosplice Therapeutics

Sector
Healthcare / BioTech & Pharma
 
 

Ginkgo Bioworks

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$4.89B

Caris Life Sciences

Sector
Healthcare / BioTech & Pharma
 
 

News Highlights

The Wall Street Journal 09/16/2022
Immunology-Drug Startup Acelyrin Raises $300 Million for Late-Stage Trials
Drugmaker Acelyrin has raised $300 million in new venture capital to run late-stage clinical trials of a drug that could treat certain forms of arthritis and other conditions and compete with top-selling medications.

Trending Companies

Frequently Asked Questions

Updated on: Dec 2, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.